These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10337431)

  • 1. Comparison of the conjunctival allergen challenge model with the environmental model of allergic conjunctivitis.
    Abelson MB
    Acta Ophthalmol Scand Suppl; 1999; (228):38-42. PubMed ID: 10337431
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic red eyes. Diagnosis: allergic conjunctivitis due to airborne allergen.
    Knopf HL; Carter K
    Compr Ophthalmol Update; 2007; 8(4):237-8. PubMed ID: 17999838
    [No Abstract]   [Full Text] [Related]  

  • 3. The anti-allergic effects of a cromolyn sodium-chlorpheniramine combination compared to ketotifen in the conjunctival allergen challenge model.
    Leonardi A; Busca F; Tavolato M; Secchi AG
    Eur J Ophthalmol; 2003 Mar; 13(2):128-33. PubMed ID: 12696630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient information. Allergic conjunctivitis.
    Am Fam Physician; 2011 Feb; 83(4):476. PubMed ID: 21322526
    [No Abstract]   [Full Text] [Related]  

  • 5. Ocular allergy: the Third Annual Thygeson Lecture, presented at the Ocular Microbiology and Immunology Group Meeting, October 25, 1997.
    Smolin G
    Cornea; 1998 May; 17(3):253-6. PubMed ID: 9603379
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.
    Brodsky M; Berger WE; Butrus S; Epstein AB; Irkec M
    Eye Contact Lens; 2003 Apr; 29(2):113-6. PubMed ID: 12695716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
    Netland PA; Leahy C; Krenzer KL
    Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
    Spangler DL; Abelson MB; Ober A; Gotnes PJ
    Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the efficacy of epinastine ophthalmic solution using a conjunctivitis allergen challenge model in patients with birch pollen allergic conjunctivitis.
    Tagawa Y; Namba K; Nakazono Y; Iwata D; Ishida S
    Allergol Int; 2017 Apr; 66(2):338-343. PubMed ID: 27720602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model.
    Friedlaender MH; Harris J; LaVallee N; Russell H; Shilstone J
    Ophthalmology; 2000 Dec; 107(12):2152-7. PubMed ID: 11097587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
    Abelson MB; Spitalny L
    Am J Ophthalmol; 1998 Jun; 125(6):797-804. PubMed ID: 9645717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of emedastine 0.05% or nedocromil sodium 2% eye drops and placebo in controlling local reactions in subjects with allergic conjunctivitis.
    Orfeo V; Vardaro A; Lena P; Mensitieri I; Tracey M; De Marco R
    Eur J Ophthalmol; 2002; 12(4):262-6. PubMed ID: 12219994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allergic diseases of the lids, conjunctiva, and cornea.
    Freissler KA; Lang GE; Lang GK
    Curr Opin Ophthalmol; 1997 Aug; 8(4):25-30. PubMed ID: 10170441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
    Fujishima H; Ohashi Y; Takamura E
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized double-blind comparison of cetirizine and fexofenadine after pollen challenge in the Environmental Exposure Unit: duration of effect in subjects with seasonal allergic rhinitis.
    Day JH; Briscoe MP; Rafeiro E; Hewlett D; Chapman D; Kramer B
    Allergy Asthma Proc; 2004; 25(1):59-68. PubMed ID: 15055564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DP2 (CRTh2) antagonism reduces ocular inflammation induced by allergen challenge and respiratory syncytial virus.
    Stebbins KJ; Broadhead AR; Musiyenko A; Barik S; Scott JM; Truong YP; Stearns BA; Hutchinson JH; Prasit P; Evans JF; Lorrain DS
    Int Arch Allergy Immunol; 2012; 157(3):259-68. PubMed ID: 22042170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
    Lanier BQ; Finegold I; D'Arienzo P; Granet D; Epstein AB; Ledgerwood GL
    Curr Med Res Opin; 2004 Aug; 20(8):1227-33. PubMed ID: 15324525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nedocromil sodium 2% ophthalmic solution for the treatment of ragweed pollen seasonal allergic conjunctivitis.
    Blumenthal MN; Schwartz RH; Kaiser H
    Ocul Immunol Inflamm; 2000 Sep; 8(3):159-67. PubMed ID: 11120577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3 Randomized Double-Masked Study of Efficacy and Safety of Once-Daily 0.77% Olopatadine Hydrochloride Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model.
    McLaurin E; Narvekar A; Gomes P; Adewale A; Torkildsen G
    Cornea; 2015 Oct; 34(10):1245-51. PubMed ID: 26266427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.